| Document |
Document Title |
|
WO/2023/060272A2 |
The present invention relates to recombinant adeno-associated viruses (rAAVs) having capsid proteins engineered to include amino acid sequences and/or amino acid substitutions that confer and/or enhance desired properties, particularly i...
|
|
WO/2023/056897A1 |
Provided is the use of a c-Abl inhibitor in the preparation of a drug for preventing and/or treating amyotrophic lateralizing sclerosis. Provided are the use of a c-Abl protein as a target in screening a drug for preventing and/or treati...
|
|
WO/2023/059590A1 |
The present disclosure relates to compositions and methods for treaty obesity-related diseases. In some aspects, methods are provided for increasing the expression and/or activity of Dj 1 protein in a subject in need thereof.
|
|
WO/2023/060097A1 |
Provided herein are methods and compositions for the treatment of ALS using chlorite or a pharmaceutical composition comprising sodium chlorite, for a target ALS patient population. Also provided herein are methods for identifying a targ...
|
|
WO/2023/055774A1 |
Provided herein are oligonucleotides, peptide-oligonucleotide-conjugates, and a targeting sequence complementary to a target region within intron 1 of a pre-mRNA of human acid alpha-glucosidase (GAA) gene having at least one purine and p...
|
|
WO/2023/054625A1 |
A problem addressed is to provide a useful means for increasing muscle mass. A composition containing threonic acid, one or more bacteria selected from Bifidobacterium spp., Lactobacillus spp., Lacticaseibacillus spp., Lactiplantibacillu...
|
|
WO/2023/054626A1 |
Provided is a cyclopropanamide derivative. A compound represented by formula (1) [wherein: n represents an integer of 0, 1, 2 or 3; ring A represents (1) 4-pyridyl which may be substituted with 1 to 4 substituents, or (2) phenyl which is...
|
|
WO/2023/056311A1 |
The disclosure provides compositions and methods for producing micro-dystrophin proteins, and the use thereof (e.g., in gene therapy). The disclosure also provides skeletal muscle- specific promoters and the use thereof (e.g., in gene th...
|
|
WO/2023/047127A1 |
The present invention is directed to a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of...
|
|
WO/2023/048277A1 |
Provided is a group 2 innate lymphoid cell growth inhibitor containing MAIT cells.
|
|
WO/2023/048504A1 |
The present invention relates to a composition for preventing or treating muscle weakness-associated diseases or sarcopenia, containing, as an active ingredient, a Rosa davurica Pallas extract, a fraction thereof or a fermented product t...
|
|
WO/2023/041713A1 |
The present invention relates to compounds having pharmacological activity towards the sigma () receptor, and more particularly to oxadiazaspiro compounds having this pharmacological activity, for use in neuroprotection or in the trea...
|
|
WO/2023/041906A1 |
The invention relates to a compound of formula (I) comprising a mitochondrial targeting group linked to a group capable of releasing hydrogen sulphide for use in the treatment of the human or animal body or tissues and cells derived ther...
|
|
WO/2023/039643A1 |
Disclosed herein are methods and related composition for administration of an antisense oligonucleotide to α4 integrin to reduce thrombospondin-1 (TSP-1), increase Latent-transforming growth factor beta-binding protein 4 (LTBP-4), and/o...
|
|
WO/2023/042158A1 |
Uses of anamorelin for improving patient reported outcomes in anorexia / cachexia patients, particularly based on patient populations who benefit from such use, and methods for defining and providing clinically meaningful treatment effects.
|
|
WO/2023/043953A1 |
Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating facioscapulohumeral muscular dystrophy (FSHD).
|
|
WO/2023/038088A1 |
The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt ...
|
|
WO/2023/036707A1 |
Substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines, salts thereof and their use as herbicidally active substances. The present invention relates to substituted 2,3-dihydro[1,3]thiazolo[4,5-b]pyridines of the general formula (I) or salt...
|
|
WO/2023/035867A1 |
The present invention relates to the field of biomedicine, and in particular to a use of goji glycopeptide in the preparation of a drug for preventing and/or treating amyotrophic lateral sclerosis. Experimental results prove the use of g...
|
|
WO/2023/038287A1 |
The present invention relates to a composition, for preventing, relieving, or treating a muscle weakness-related disease, comprising a celery seed extract. The celery seed extract according to the present invention causes a few or no sid...
|
|
WO/2022/216988A9 |
A library of artificial muscle-specific expression cassettes (MSECs) for muscle-specific gene expression is described. Different members of the library can be selected for varied transcription levels in different muscle cell types, for d...
|
|
WO/2023/038506A1 |
The present invention relates to a composition for preventing, alleviating, or treating muscle weakness-related diseases, containing an extract of foxtail as an active ingredient. The foxtail extract according to the present invention ha...
|
|
WO/2023/031862A1 |
Provided is a method for treating a condition related to cannabinoid type 1 (CB1) receptor activation by administering a composition comprising at least one terpene, optionally together with tetrahydrocannabinol (THC). Further provided i...
|
|
WO/2023/033050A1 |
Disclosed are: a bornavirus vector capable of binding to a mutant SOD1 protein and carrying a nucleic acid encoding an antibody or antibody fragment, in which the antibody or antibody fragment contains a heavy-chain variable region that ...
|
|
WO/2023/031840A1 |
The invention concerns LOU064 or a pharmaceutically acceptable salt thereof for use in the effective treatment of multiple sclerosis (MS).
|
|
WO/2023/032940A1 |
The present invention provides a compound which has PDHK inhibitory activity and which is useful for treating or preventing diabetes (type 1 diabetes, type 2 diabetes, etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia...
|
|
WO/2023/031673A1 |
The invention provides methods useful for treating post-viral illness, including long COVID-19, in a subject afflicted therewith comprising administering to the subject an urolithin.
|
|
WO/2023/025861A1 |
The present invention concerns a compound of formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, wherein X, R1, R2, R3 are defined, a conjugate thereof and their uses as drug or research tools.
|
|
WO/2023/026043A1 |
The present invention relates to nutritional compositions for maintaining and enhancing one carbon (1C) metabolism. The compositions are useful for maintaining general body health, reducing physiological consequences of metabolic stress,...
|
|
WO/2023/025914A1 |
The present invention relates to compositions and kits for influencing, in a targeted manner, energy metabolism in muscular and fatty tissue. In detail, the invention teaches a composition or a kit which provides the three components ins...
|
|
WO/2022/253794A9 |
The present invention relates to methods for the prevention, delay of progression or treatment of an autoimmune and inflammatory disease (AIID) in a subject.
|
|
WO/2023/027317A1 |
The present invention relates to a composition for the prevention, alleviation or treatment of muscle loss-related diseases, comprising exosomes derived from tonsil mesenchymal stem cells. The composition of the present invention contain...
|
|
WO/2023/025101A1 |
Provided are methods and compounds for enhancing mitochondrial biogenesis in a mammal or for activating PGC-1α in a mammal, comprising administrating to the mammal in need thereof a therapeutically effective amount of L-Ergothioneine, a...
|
|
WO/2023/027540A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of muscle diseases, comprising ginsenoside Rc. Ginsenoside Rc inhibits myoblast apoptosis under oxidative stress, increases the activity of PGC1...
|
|
WO/2023/026994A1 |
The purpose of the present invention is to provide novel drug delivery system (DDS) technology that makes it possible to selectively deliver a drug (a compound containing oligonucleotide for producing an at least partially functional dys...
|
|
WO/2023/022229A1 |
The present invention addresses the problem of providing a new double-stranded nucleic acid complex having superior activity. Provided is a double-stranded nucleic acid complex containing a first nucleic acid chain and a second nucleic...
|
|
WO/2023/019823A1 |
Disclosed in the present invention are a new use of desloratadine (DLT) and a pharmaceutically acceptable salt thereof in the preparation of a drug for treating neurodegenerative diseases related to motor dysfunction. According to the pr...
|
|
WO/2022/200523A9 |
The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compound...
|
|
WO/2023/017739A1 |
The purpose of the present invention is to provide a composition for preventing or ameliorating locomotive syndrome that means a condition at an increased risk for requiring nursing care due to decline in mobility caused by deteriorated ...
|
|
WO/2023/017424A1 |
The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to da...
|
|
WO/2023/016852A1 |
The present invention relates to a composition for oral subministration, as food supplementation or medical purposes and, in particular, to a composition comprising amino acids, which is effective as a vasodilator and/or in a method for ...
|
|
WO/2023/019189A1 |
This invention relates to methods and compositions for gene therapy. In particular, the invention relates to compositions for enhancing delivery of therapeutic products to bystander cells that have not received the expression vector enco...
|
|
WO/2023/011076A1 |
Disclosed in the present invention are a multi-target complex of a loaded liposome and a drug-loaded platform containing same and an application. The multi-target complex of the loaded liposome contains: a stimulator of interferon genes ...
|
|
WO/2023/015297A1 |
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specifi...
|
|
WO/2023/015304A1 |
The invention provides intrathecal compositions comprising AAV particles, and their use for treating monogenic muscle disorders such as dystrophinopathies, including Duchenne muscular dystrophy.
|
|
WO/2023/012334A1 |
The present invention relates to myogenic progenitor cells (MFCs) for use in a method for the prevention and/or treatment of anal incontinence in a subject, wherein said subject is at risk to develop anal incontinence or suffers from ana...
|
|
WO/2023/012371A1 |
The invention pertains to a nutritional composition for use in prevention and/or treatment of whole body protein metabolism decline or whole body protein function decline, or for therapeutic use in improving whole body protein metabolism...
|
|
WO/2023/014160A1 |
The present invention relates to a crystalline form of a phenyl carbamate derivative compound and uses thereof, and more specifically, the present invention relates to a pattern 1 crystalline form, which is a thermodynamically more stabl...
|
|
WO/2023/008913A1 |
The present invention relates to an optimized shortened peptide that binds to an acetylcholine receptor, and a use thereof. It is expected that it is possible to develop a cosmetic composition for alleviating wrinkles, pharmaceuticals fo...
|
|
WO/2023/009672A1 |
Provided herein, in part, are methods of treating facioscapulohumeral muscular dystrophy in a patient in need thereof, comprising administering losmapimod to the patient.
|
